Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022
Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research

1.5. ANALYST TOOLS AND MODELS

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY MARKET, 2015

3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market Size and Forecast

4.2. MONOCLONAL ANTIBODIES

4.2.1. Key Market Trends
4.2.2. Key Growth Factors and Opportunities
4.2.3. Market Size and Forecast

4.4. CYTOKINES & IMMUNOMODULATORS

4.4.1. Key Market Trends
4.4.2. Key Growth Factors And Opportunities
4.4.3. Market Size And Forecast

4.5. OTHER TECHNOLOGY

4.5.1. Key Market Trends
4.5.2. Key Growth Factors And Opportunities
4.5.3. Market Size And Forecast

CHAPTER 5 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LUNG CANCER

5.2.1. Market size and forecast

5.3. BREAST CANCER

5.3.1. Market size and forecast

5.4. COLORECTAL CANCER

5.4.1. Market size and forecast

5.5. MELANOMA

5.5.1. Market size and forecast

5.6. PROSTATE CANCER

5.6.1. Market size and forecast

5.7. HEAD & NECK CANCER

5.7.1. Market size and forecast

5.8. OTHER CANCER

5.8.1. Market size and forecast

CHAPTER 6 CANCER IMMUNOTHERAPY MARKET, BY END USER

6.1. OVERVIEW
6.1.1. Market size and forecast

6.2. HOSPITAL

6.2.1. Market size and forecast

6.3. CANCER RESEARCH CENTERS

6.3.1. Market size and forecast

6.4. CLINICS

6.4.1. Market size and forecast

CHAPTER 7 MULTIPLEX ASSAYS MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities.
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. AMGEN INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. ADVAXIS INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. MERCK & CO., INC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. ELI LILLY AND COMPANY

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. BRISTOL-MYERS SQUIBB COMPANY

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. PFIZER INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. NOVARTIS AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. BAYER AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. IMMUNOMEDICS INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance

8.9.6. Key strategic moves and developments

8.10. ASTRAZENECA PLC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

Additional Details

Publisher: Allied Market Research
Reference: LI 172244
Number of Pages: 150
Report Format: PDF
Publisher Information:

- LIST OF TABLES
  - TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY, 2014-2022, ($MILLION)
  - TABLE 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, FOR, BY REGION, 2014-2022, ($MILLION)
  - TABLE 3. GLOBAL CANCER CYTOKINES & IMMUNOMODULATORS MARKET, BY REGION, 2014-2022, ($MILLION)
  - TABLE 4. GLOBAL OTHER CANCER IMMUNOTHERAPY MARKET, BY REGION, 2014-2022, ($MILLION)
  - TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2014-2022, ($MILLION)
  - TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR LUNG CANCER, BY REGION, 2014-2022, ($MILLION)
  - TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR BREAST CANCER, BY REGION, 2014-2022, ($MILLION)
  - TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR COLORECTAL CANCER, BY REGION, 2014-2022, ($MILLION)
  - TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR MELANOMA, BY REGION, 2014-2022, ($MILLION)
  - TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR PROSTATE CANCER, BY REGION, 2014-2022, ($MILLION)
  - TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR HEAD & NECK CANCER, BY REGION, 2014-2022, ($MILLION)
  - TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR OTHER CANCERS, BY REGION, 2014-2022, ($MILLION)
  - TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END-USER, 2014-2022, ($MILLION)
  - TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR HOSPITALS, BY REGION, 2014-2022, ($MILLION)
  - TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR CANCER RESEARCH CENTRES, BY REGION, 2014-2022, ($MILLION)
  - TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR CLINICS, BY REGION, 2014-2022, ($MILLION)
  - TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION, 2014-2022, ($MILLION)
  - TABLE 18. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY COUNTRY, 2014-2022, ($MILLION)
  - TABLE 19. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY TECHNOLOGY, 2014-2022, ($MILLION)
  - TABLE 20. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY APPLICATION, 2014-2022, ($MILLION)
  - TABLE 21. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY END-USER, 2014-2022, ($MILLION)
  - TABLE 22. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY COUNTRY, 2014-2022, ($MILLION)
  - TABLE 23. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY TECHNOLOGY, 2014-2022, ($MILLION)
  - TABLE 24. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY APPLICATION, 2014-2022, ($MILLION)
  - TABLE 25. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY END-USER, 2014-2022, ($MILLION)
  - TABLE 26. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY COUNTRY, 2014-2022, ($MILLION)
  - TABLE 27. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY TECHNOLOGY, 2014-2022, ($MILLION)
  - TABLE 28. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY APPLICATION, 2014-2022, ($MILLION)
  - TABLE 29. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY COUNTRY, 2014-2022, ($MILLION)
  - TABLE 30. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY TECHNOLOGY, 2014-2022, ($MILLION)
  - TABLE 31. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY END-USER, 2014-2022, ($MILLION)
  - TABLE 32. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY APPLICATION, 2014-2022, ($MILLION)
  - TABLE 33. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY COMPANY, 2014-2022, ($MILLION)
  - TABLE 34. AMGEN INC. - COMPANY SNAPSHOT
  - TABLE 35. ADVAXIS INC. - COMPANY SNAPSHOT
  - TABLE 36. MERCK & CO., INC. - COMPANY SNAPSHOT
  - TABLE 37. ELI LILLY AND COMPANY - COMPANY SNAPSHOT
  - TABLE 38. BRISTOL-MYERS SQUIBB COMPANY - COMPANY SNAPSHOT
  - TABLE 39. PFIZER INC. - COMPANY SNAPSHOT
  - TABLE 40. NOVARTIS AG - COMPANY SNAPSHOT
  - TABLE 41. BAYER AG - COMPANY SNAPSHOT
  - TABLE 42. IMMUNOMEDICS INC. - COMPANY SNAPSHOT
  - TABLE 43. ASTRAZENECA PLC. - COMPANY SNAPSHOT

- LIST OF FIGURES
  - FIGURE 1. CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY, 2014-2022
IMMUNOTHERAPY: MARKET SEGMENTATION

FIGURE 2. TOP INVESTMENT POCKETS

FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)

FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 5. MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY, 2015


FIGURE 7. CANCER IMMUNOTHERAPY: CYTOKINES & IMMUNOMODULATORS MARKET, 2014-2022, ($MILLION)

FIGURE 8. CANCER IMMUNOTHERAPY: LUNG CANCER MARKET, 2014-2022, ($MILLION)


FIGURE 10. CANCER IMMUNOTHERAPY: COLORECTAL CANCER MARKET, 2014-2022, ($MILLION)

FIGURE 11. CANCER IMMUNOTHERAPY: MELANOMA MARKET, 2014-2022, ($MILLION)

FIGURE 12. CANCER IMMUNOTHERAPY: PROSTATE CANCER MARKET, 2014-2022, ($MILLION)


FIGURE 15. CANCER IMMUNOTHERAPY: HOSPITALS MARKET, 2014-2022, ($MILLION)


FIGURE 17. CANCER IMMUNOTHERAPY: CLINICS MARKET, 2014-2022, ($MILLION)


FIGURE 19. CANCER IMMUNOTHERAPY: CANADA MARKET, 2014-2022, ($MILLION)

FIGURE 20. CANCER IMMUNOTHERAPY: MEXICO MARKET, 2014-2022, ($MILLION)


FIGURE 22. CANCER IMMUNOTHERAPY: GERMANY MARKET, 2014-2022, ($MILLION)

FIGURE 23. CANCER IMMUNOTHERAPY: FRANCE MARKET, 2014-2022, ($MILLION)


FIGURE 25. CANCER IMMUNOTHERAPY: REST OF EUROPE MARKET, 2014-2022, ($MILLION)


FIGURE 27. CANCER IMMUNOTHERAPY: INDIA MARKET, 2014-2022, ($MILLION)


FIGURE 29. CANCER IMMUNOTHERAPY: LATIN AMERICA MARKET, 2014-2022, ($MILLION)

FIGURE 30. CANCER IMMUNOTHERAPY: MIDDLE EAST MARKET, 2014-2022, ($MILLION)

How to Buy...


Option 1 - Online
Go to our website and pay online with any major debit or credit card:

https://www.bioportfolio.co.uk/product/103573

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ........................................................................................................
Job Title: ........................................................................................................
Your Email: ....................................................................................................
Your Contact Phone: ....................................................................................
Company Name: ...........................................................................................
Address: ........................................................................................................
Post/Zip Code: ..............................................................................................
Country: ........................................................................................................
P.O. Number: ................................................................................................
Any Other Instructions: ...................................................................................

Pricing Options: (please tick one)
● $5370 | Single User Price
● $5910 | Five User License Price
● $7800 | Enterprise License Price

Payment Options: (please tick one)
● Online Credit Card (we will email you the invoice with a payment link)
● Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ....................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.

https://www.bioportfolio.co.uk/product/103573
pdb@bioportfolio.co.uk to order

© BioPortfolio Limited - 2019